{"id":2261,"date":"2014-03-01T12:02:00","date_gmt":"2014-03-01T11:02:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2014\/neues-onkologisches-arzneimittel-trastuzumab-emtansin"},"modified":"2014-03-01T12:02:00","modified_gmt":"2014-03-01T11:02:00","slug":"neues-onkologisches-arzneimittel-trastuzumab-emtansin","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2014\/neues-onkologisches-arzneimittel-trastuzumab-emtansin","title":{"rendered":"Neues onkologisches Arzneimittel: Trastuzumab Emtansin"},"content":{"rendered":"<p>Trastuzumab (Herceptin\u00ae) ist ein monoklonaler Antik\u00f6rper gegen den Rezeptor des humanen epidermalen Wachstumsfaktors 2 (HER2), der in der Therapie des HER2-positiven Brustkrebses fest etabliert ist. Er wird in der Mono- und Kombinationstherapie des metastasierten Mammakarzinoms eingesetzt, aber auch im Fr\u00fchstadium der Erkrankung in der neoadjuvanten (pr\u00e4operativen) oder adjuvanten Behandlung (1, vgl. 2). Das Patent f\u00fcr [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Trastuzumab (Herceptin\u00ae) ist ein monoklonaler Antik\u00f6rper gegen den Rezeptor des humanen epidermalen Wachstumsfaktors 2 (HER2), der in der Therapie des HER2-positiven Brustkrebses fest etabliert ist. Er wird in der Mono- und Kombinationstherapie des metastasierten Mammakarzinoms eingesetzt, aber auch im Fr\u00fchstadium der Erkrankung in der neoadjuvanten (pr\u00e4operativen) oder adjuvanten Behandlung (1, vgl. 2). Das Patent f\u00fcr [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[146,1903,1906,222,149,2753],"class_list":["post-2261","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-brustkrebs","tag-her2","tag-human-epidermal-growth-factor-receptor-2","tag-karzinome","tag-mammakarzinom","tag-trastuzumab-emtansin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2261"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2261\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}